QFR Solutions
LinkedIn
QFR Solutions

Encore Dermatology Inc. Announces Launch of TridesilonTM (desonide) Cream, 0.05%

Source: Business Wire

Encore Dermatology Inc. Announces Launch of TridesilonTM (desonide) Cream, 0.05%

Encore Dermatology Inc., a privately held dermatology company that specializes in developing and commercializing novel prescription products for improving skin health, announced today the availability of TridesilonTM (desonide) Cream, 0.05% in a 60g tube. TridesilonTM Cream, 0.05% is a low-potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Encore Dermatology Inc. has licensed TridesilonTM Cream, 0.05% from Perrigo Company plc (NYSE, TASE: PRGO).

“Atopic dermatitis is a challenge to treat because of the chronic and cyclical nature of the disease,” Dr. Guy Webster, professor of dermatology, said. “Desonide has been one of the most widely used steroids for years in dermatology to treat various types of dermatoses because of its reliable efficacy and safety profile.”

TridesilonTM Cream, 0.05% is available in the U.S. by prescription only.

“Our goal at Encore Dermatology is to offer a wide variety of products to dermatology providers to help manage their eczema patients,” Bob Moccia, president and CEO of Encore Dermatology, said.

“With the addition of TridesilonTM Cream, 0.05%, Encore Dermatology will now offer healthcare providers numerous options, including HylatopicPlus® Cream or Lotion and Tetrix® Cream, when it comes to treating and managing their eczema patients,” Moccia said. “We are especially excited to launch TridesilonTM Cream, 0.05% because when healthcare providers prescribe desonide for dermatoses, creams are the No. 1 prescribed formulation.”1

Important Safety Information for TridesilonTM Cream, 0.05%

TridesilonTM Cream, 0.05% is a low-potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. It should not be used for longer than two weeks unless directed by a physician. TridesilonTM Cream, 0.05% is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

TridesilonTM Cream, HylatopicPlus® and Tetrix® Cream are not indicated for combination use.

Our Office

QFR Solutions
8360 E. Raintree Drive Suite 245
Scottsdale, Arizona 85260

Contact Us

Phone: 480.907.7690
Fax: 877.320.1387
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Career Opportunities

QFR is always looking for the best and the brightest talent to join our team.
This email address is being protected from spambots. You need JavaScript enabled to view it.

LinkedIn